Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179016 | 1.00 | HTR6 (0.42) | HTR6CNR1CNR2CYP2D6CYP3A4 | |
| SCHEMBL1179188 | 0.84 | HTR6 (0.49) | HTR6CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1179190 | 0.84 | HTR6 (0.49) | HTR6CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7987499 | 0.84 | HTR6 (0.49) | HTR6CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7998160 | 0.84 | HTR6 (0.55) | HTR6LMNA | |
| SCHEMBL1179248 | 0.84 | HTR6 (0.55) | HTR6LMNA | |
| SCHEMBL1179246 | 0.84 | HTR6 (0.55) | HTR6LMNA | |
| SCHEMBL12886467 | 0.76 | HTR6 (0.45) | HTR6CNR1CNR2 | |
| SCHEMBL12872069 | 0.75 | HTR6 (0.41) | HTR6CYP2D6CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6885348 | 0.74 | HTT (0.49) | HTR6KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610247-B1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LTD (BS) | 2016-05-25 | — | — | EP | disclosed |
| EP-2265589-B1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LTD (BS) | 2016-01-27 | — | — | EP | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2610247-A1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbott Healthcare Products B.V. (NL) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
| EP-2265589-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | Abbott Healthcare Products B.V. (NL) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115515-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885CNR1 38/4885CNR2 20/4885 |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885CNR1 38/4885CNR2 20/4885 |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | HTR6 1/4885CNR1 38/4885CNR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.